埃博拉疫苗有望在两年内投放市场

2016-01-21 佚名 cnBeta

据外媒报道，全球疫苗免疫联盟(Gavi)今天在世界经济论坛上同意向美国制药业巨头默克(Merck & Co)捐款500万美金，支持该公司尽快将已进入临床试验的埃博拉疫苗投放于市场。这一协议也要求默克公司的埃博拉疫苗在2017年年底获得监管机构批准，同时该公司需要在今年五月底之前生产至少30万剂量的疫苗，用于临床试验及紧急情况。不过Gavi表示突发公共卫生事件情况下使用的临床实验性疫苗需

据外媒报道，全球疫苗免疫联盟(Gavi)今天在世界经济论坛上同意向美国制药业巨头默克(Merck & Co)捐款500万美金，支持该公司尽快将已进入临床试验的埃博拉疫苗投放于市场。这一协议也要求默克公司的埃博拉疫苗在2017年年底获得监管机构批准，同时该公司需要在今年五月底之前生产至少30万剂量的疫苗，用于临床试验及紧急情况。

不过Gavi表示突发公共卫生事件情况下使用的临床实验性疫苗需要首先获得世界卫生组织的特别审批。

由默克公司开发的埃博拉疫苗已在几内亚的一次大规模测试中被证明非常有效，总共有4000多人被注射了由这家公司开发的疫苗。这些被接种者都曾与已确认感染了埃博拉病毒的患者进行过亲密接触，测试结果显示，该疫苗成功地为被接种者提供了100%的保护。

世界卫生组织上周宣布，西非三个埃博拉疫情最严重国家在42天内没有收到新的埃博拉病毒的报告。然而在上述声明发布不久，世界卫生组织又宣布塞拉利昂出现新的埃博拉死亡病例。据统计，埃博拉疫情已在全球造成28600人感染,超过11300人死亡。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-27 文医生

静候喜讯

93 0
[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-27 李继凯

喜讯

150 0
[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-27 李继凯

辛苦了

118 0
[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-23 yourmama

#埃博拉疫苗#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-22 胖胖7598

赞一个

131 0
[GetPortalCommentsPageByObjectIdResponse(id=61438, encodeId=4c9f6143851, content=静候喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61069, encodeId=4ec76106992, content=喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61070, encodeId=d027610e002, content=辛苦了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:28:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460054, encodeId=2ce914600547d, content=<a href='/topic/show?id=d44f415583a' target=_blank style='color:#2F92EE;'>#埃博拉疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41558, encryptionId=d44f415583a, topicName=埃博拉疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78136234994, createdName=yourmama, createdTime=Sat Jan 23 08:25:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58746, encodeId=1eae58e46cc, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8941653912, createdName=胖胖7598, createdTime=Fri Jan 22 10:24:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58703, encodeId=384f58e03ed, content=这是喜讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/17/3872cad7a53dc9dcbd08202fb6313cf4.jpg, createdBy=2cb71609450, createdName=KO229256262, createdTime=Thu Jan 21 21:17:00 CST 2016, time=2016-01-21, status=1, ipAttribution=)]
2016-01-21 KO229256262

这是喜讯

130 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

埃博拉疫苗有望在两年内投放市场

相关资讯

科室

工具

服务